Krystal Biotech (KRYS) fundamentals: P/E, valuation, undervalued?
Krystal Biotech · Health Care · ref. ETF XLV · price $357.46
In short — Krystal Biotech trades at 44.7× earnings (P/E), 38.0× forward, with a net margin of 54.8 % and revenue growth of +24 %. Read: Cheap for the growth (P/E 38 for ~39% growth (PEG 1.0)).
Is Krystal Biotech stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$357.46+137.1% over range
Aug 28, 25low $137.46 · high $378.15Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
86% recommend buying · 7 analysts
Valuation : Cheap for the growth — P/E 38 for ~39% growth (PEG 1.0)
Valuation
44.7
P/E (price/earnings)
38.0
Forward P/E
1.15
PEG
8.2
Price/book (P/B)
$10.6B
Market cap
7.99
EPS
Profitability & growth
54.8 %
Net margin
+24 %
Revenue growth
+39 %
Earnings growth
$9M
Total debt
Krystal Biotech income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $0 | $-140M | — |
| 2023 | $51M | $11M | 21.6 % |
| 2024 | $291M | $89M | 30.7 % |
| 2025 | $389M | $205M | 52.6 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Krystal Biotech's P/E and is the stock undervalued? What's a good P/E?
Krystal Biotech's P/E is 44.7 (forward 38.0). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is Krystal Biotech profitable?
Krystal Biotech has a net margin of 54.8 % (EPS 7.99). The company is profitable.
Is KRYS stock expensive?
Our read: "Cheap for the growth" — P/E 38 for ~39% growth (PEG 1.0). Cross-check with growth and sector.
💬 A question about Krystal Biotech? The JPI assistant answers using our backtest data.
Keep exploring Krystal Biotech